Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
ETHK Labs's 3-Year RORE % for the quarter that ended in Dec. 2025 was -67.87%.
The industry rank for ETHK Labs's 3-Year RORE % or its related term are showing as below:
HKSE:01931's 3-Year RORE % is ranked worse than 92.86% of 112
companies
in the Medical Distribution industry
Industry Median: 8.36
vs HKSE:01931: -67.87
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
ETHK Labs 3-Year RORE % Related Terms
ETHK Labs 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for ETHK Labs's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01931 vs MCK, COR, CAH: 3-Year RORE % Comparison
For the Medical Distribution subindustry, ETHK Labs's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ETHK Labs 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ETHK Labs's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where ETHK Labs's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
ETHK Labs (HKSE:01931) has a 3-Year RORE % of -67.87 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ETHK Labs and its competitors. According to the industry distribution chart, ETHK Labs ranks #104 out of 112 companies in the Medical Distribution industry, placing it in the top 92.9%.
Is ETHK Labs' 3-Year RORE % too high?
ETHK Labs' current 3-Year RORE % is -67.87. Based on the distribution chart, ETHK Labs ranks #104 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, ETHK Labs has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ETHK Labs' 3-Year RORE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ETHK Labs ranks #104 out of 112 companies for 3-Year RORE %. This places ETHK Labs in the lower half of its industry. The industry median 3-Year RORE % is 8.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 8.36, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ETHK Labs and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 8.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ETHK Labs's current 3-Year RORE % is -67.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ETHK Labs stock overvalued right now?
Based on GuruFocus' analysis, ETHK Labs (HKSE:01931) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.37, compared to a current price of HK$0.61 — trading 55.8% below its estimated fair value. The current 3-Year RORE % is -67.87. ETHK Labs' overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ETHK Labs (HKSE:01931), the current 3-Year RORE % is -67.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ETHK Labs (HKSE:01931) Overvalued in 2026?
Based on GuruFocus' analysis, ETHK Labs stock appears to be undervalued.
The current stock price of HK$0.61 is trading 55.8% below its estimated GF Value™ of HK$1.37.
GuruFocus considers ETHK Labs to be Possible Value Trap.
Key valuation signals for HKSE:01931:
3-Year RORE %: -67.87
GF Value™: HK$1.37 vs. price of HK$0.61 (55.8% below fair value)
No single metric tells the full story. See the HKSE:01931 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ETHK Labs Inc is engaged in the distribution, after-sales service, and development of in-vitro diagnostic (IVD) products in China. The company operates through three business segments: Distribution Business, After-sales Services, and Self-branded Products Business. It distributes IVD analysers, reagents, and consumables to hospitals and healthcare institutions, provides maintenance and installation services for diagnostic equipment, and develops and sells self-branded IVD analysers and reagents. The company generates the majority of its revenue from Mainland China.
74GF Score
Get the complete analysis for HKSE:01931
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01931 has been successfully added to your 
